Tenaya Therapeutics (TNYA)
(Delayed Data from NSDQ)
$2.72 USD
+0.07 (2.64%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $2.73 +0.01 (0.37%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TNYA 2.72 +0.07(2.64%)
Will TNYA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TNYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TNYA
Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross?
Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet
TNYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's Why
Wall Street Analysts Believe Tenaya Therapeutics, Inc. (TNYA) Could Rally 217.58%: Here's is How to Trade
Tenaya Therapeutics, Inc. (TNYA) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for TNYA
Tenaya Therapeutics: A Buy Recommendation Based on Clinical Progress and Financial Fortitude
Buy Rating Affirmed for Tenaya Therapeutics: Strong Clinical Progress and Strategic Financial Positioning
TNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q2 2024
Piper Sandler Sticks to Its Buy Rating for Tenaya Therapeutics (TNYA)
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), GoodRx Holdings (GDRX) and Tenaya Therapeutics (TNYA)